The aim of this study was to examine the benefit of adding radiation therapy to androgen deprivation therapy (ADT) for metastatic prostate cancer. Researchers reported a significant survival advantage when radiation therapy was combined with ADT.

This study evaluated the effectiveness and safety of apalutamide (Erleada) in combination with abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that apalutamide plus AAP combination significantly improved survival without progression or cancer worsening in these patients.

This study reported the long-term effects on the health-related quality of life (HR-QoL) of apalutamide (Erleada) in combination with androgen deprivation therapy (ADT) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). The data showed that apalutamide plus ADT preserved HR-QoL in these patients.

The study assessed the frequency of bone density testing among prostate cancer patients treated with androgen-deprivation therapy. 

The authors evaluated the prevalence and management of urethral blockage following certain cancer treatments.

This study investigated the impact of age, comorbidities (the existence of other illnesses), and tumor risk on mortality in men with early-stage prostate cancer.

This study evaluated the effectiveness and safety outcomes of talazoparib (Talzenna) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in DNA repair genes. The data showed that talazoparib was effective with manageable side effects for these patients.

This study aimed to investigate the link between various treatments for castration-resistant prostate cancer (CRPC) and cognitive (mental) dysfunction in older men. The main finding was that the treatments assessed did not appear to have an impact on cognitive function.